Financials data is unavailable for this security.
View more
Year on year SAB Biotherapeutics Inc 's revenues fell -90.63% from 23.90m to 2.24m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 18.74m to a larger loss of 42.19m.
| Gross margin | -- |
|---|---|
| Net profit margin | -1,450.32% |
| Operating margin | -1,647.03% |
| Return on assets | -82.85% |
|---|---|
| Return on equity | -122.49% |
| Return on investment | -102.37% |
More ▼
Cash flow in USDView more
In 2023, SAB Biotherapeutics Inc increased its cash reserves by 275.93%, or 41.52m. Cash Flow from Financing totalled 66.77m or 2,982.29% of revenues. In addition the company used 25.12m for operations while cash used for investing totalled 152.70k.
| Cash flow per share | -4.62 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.00 |
|---|---|
| Tangible book value per share | 5.00 |
More ▼
Balance sheet in USDView more
| Current ratio | 5.24 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.0889 |
|---|---|
| Total debt/total capital | 0.0817 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -77.48%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 8.50 |
